McClarren Financial Advisors Inc. Takes Position in McKesson Co. (NYSE:MCK)

McClarren Financial Advisors Inc. bought a new position in shares of McKesson Co. (NYSE:MCK) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 371 shares of the company’s stock, valued at approximately $172,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Stanley Laman Group Ltd. grew its holdings in shares of McKesson by 0.9% during the fourth quarter. Stanley Laman Group Ltd. now owns 8,431 shares of the company’s stock worth $3,903,000 after purchasing an additional 72 shares during the last quarter. AM Investment Strategies LLC purchased a new position in McKesson during the 4th quarter worth approximately $229,000. Motley Fool Asset Management LLC increased its position in McKesson by 4.6% during the fourth quarter. Motley Fool Asset Management LLC now owns 3,951 shares of the company’s stock worth $1,829,000 after buying an additional 172 shares during the period. Stevens Capital Management LP lifted its stake in McKesson by 107.5% in the fourth quarter. Stevens Capital Management LP now owns 2,723 shares of the company’s stock valued at $1,261,000 after buying an additional 1,411 shares during the last quarter. Finally, Syon Capital LLC boosted its holdings in shares of McKesson by 40.7% in the fourth quarter. Syon Capital LLC now owns 2,538 shares of the company’s stock valued at $1,175,000 after acquiring an additional 734 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Performance

McKesson stock traded up $4.52 during midday trading on Thursday, reaching $539.94. The company’s stock had a trading volume of 446,710 shares, compared to its average volume of 686,906. The firm has a market capitalization of $70.95 billion, a PE ratio of 24.46, a P/E/G ratio of 1.41 and a beta of 0.45. McKesson Co. has a fifty-two week low of $352.34 and a fifty-two week high of $543.00. The stock’s 50 day simple moving average is $527.50 and its 200 day simple moving average is $488.84.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating the consensus estimate of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The firm had revenue of $80.90 billion during the quarter, compared to analysts’ expectations of $77.93 billion. During the same quarter last year, the business earned $6.90 earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities analysts predict that McKesson Co. will post 27.59 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 0.46%. The ex-dividend date is Monday, June 3rd. McKesson’s payout ratio is currently 11.24%.

Insider Buying and Selling

In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares in the company, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on MCK shares. Citigroup upped their price target on shares of McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. StockNews.com raised McKesson from a “buy” rating to a “strong-buy” rating in a report on Thursday. Morgan Stanley upped their price objective on McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a research note on Monday, April 15th. Barclays began coverage on McKesson in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price objective for the company. Finally, SVB Leerink began coverage on McKesson in a report on Monday, February 26th. They issued an “outperform” rating and a $600.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $533.50.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.